Talzenna 1 mg Alternative – Talaparib (Talazoparib) 1 mg Capsule | Everest Pharmaceuticals
Talaparib 1 mg (Talazoparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Talzenna (Pfizer). It belongs to the PARP inhibitor class and is used in selected genetically defined breast and prostate cancer treatment settings.
Active ingredient: Talazoparib
Strength: 1 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Talaparib 1 mg Capsule by Everest Pharmaceuticals Ltd., Bangladesh contains Talazoparib. It is listed here as a same-ingredient branded option for people researching Talzenna, a reference brand associated with Pfizer. Talaparib and Talzenna must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 1 mg strength.
Talaparib vs. Talzenna – Originator / Reference Brand Comparison
Talzenna is a widely recognized reference brand for Talazoparib associated with Pfizer. Talaparib is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Talaparib is manufactured by Pfizer, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Talazoparib
Strength: 1 mg
Dosage form: Capsule
Pharmacological class: PARP inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Talazoparib is used in selected genetically defined breast and prostate cancer treatment settings. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Talazoparib Works
Talazoparib is a PARP inhibitor. In general, it impairs PARP-dependent DNA repair in susceptible cancer cells. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 1 mg per capsule; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Talazoparib include: anemia, low blood counts and embryo-fetal harm. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Talazoparib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include anemia, low blood counts and embryo-fetal harm. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Talazoparib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Talazoparib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Talaparib Listed as an Alternative to Talzenna?
This listing helps customers identify an Everest Pharmaceuticals product containing Talazoparib while researching Talzenna. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Talaparib
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Talzenna
Reference company: Pfizer
Generic ingredient: Talazoparib
Strength: 1 mg
Dosage form: Capsule
Therapeutic class: PARP inhibitor
Frequently Asked Questions
What is Talaparib 1 mg?
It is an Everest Pharmaceuticals capsule containing Talazoparib 1 mg.
Is Talaparib the same as Talzenna?
They are presented as brands associated with Talazoparib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Talazoparib used for?
Talazoparib is used in selected genetically defined breast and prostate cancer treatment settings, subject to the applicable label and clinical assessment.
How does Talazoparib work?
It impairs PARP-dependent DNA repair in susceptible cancer cells.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Talazoparib |
|---|---|
| Strength | 1 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 30 capsules |
Related products
Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Kisqali 200 mg Alternative – Ribolib (Ribociclib) 200 mg Tablet | Beacon Pharmaceuticals
Lonsurf 15 mg / 6.14 mg Alternative – Trifluxen (Trifluridine 15 mg + Tipiracil 6.14 mg) 15 mg / 6.14 mg Tablet | Everest Pharmaceuticals
Trifluxen 15 mg / 6.14 mg (Trifluridine 15 mg + Tipiracil 6.14 mg) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lonsurf (Taiho Oncology). It belongs to the trifluridine/tipiracil combination class and is used in selected previously treated metastatic colorectal cancer and other authorized settings.
Active ingredient: Trifluridine 15 mg + Tipiracil 6.14 mg
Strength: 15 mg / 6.14 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals
Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.
Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tykerb 250 mg Alternative – Certus (Lapatinib) 250 mg Tablet | Beacon Pharmaceuticals
Votrient 200 mg Alternative – Pazorest (Pazopanib) 200 mg Tablet | Everest Pharmaceuticals
Pazorest 200 mg (Pazopanib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Votrient (Novartis). It belongs to the multitarget kinase inhibitor class and is used in selected advanced renal cell carcinoma and soft tissue sarcoma.
Active ingredient: Pazopanib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.